Abstract
The authors examined cognitive changes associated with treatment with ziprasidone and olanzapine over a 6-month double-blind clinical trial, using normative standards for the cognitive measures. Sixty-two schizophrenia patients entered the study on ziprasidone treatment (39 completers), and 71 patients entered while receiving treatment with olanzapine (33 completers). From a larger set of cognitive domains assessed in the acute treatment study, we selected verbal learning, executive functioning, and verbal fluency for further analysis due to their functional relevance and extensive normative data. Standard scores were developed based on previously published age- and education-corrected norms. Baseline performance was impaired across all tests on average. The proportion of patients impaired on each of the tests at baseline ranged from 36% (letter fluency) to 89%. Performance was significantly improved by ziprasidone and olanzapine treatment for all cognitive variables and for the composite measure. A number of subjects met the a priori criteria for normalization in performance, ranging from 10% for Trail Making Test Part B to 37% for Word List Total Learning. There were no significant differences across medications in extent of ...Continue Reading
Citations
Jul 1, 2006·Psychopharmacology·Robert S KernRon Marcus
Mar 8, 2007·Expert Review of Neurotherapeutics·Christopher R Bowie, Kushik Jaga
Feb 5, 2009·Schizophrenia Research·Philip D HarveyCharlotte M Kremer
Jan 29, 2008·Psychiatry Research·Hiroaki HoriHiroshi Kunugi
Jan 20, 2015·Acta Psychiatrica Scandinavica·R E NielsenS Leucht
Oct 27, 2010·Clinical and Translational Science·William T AbrahamCesare Orlandi
Sep 1, 2015·Frontiers in Behavioral Neuroscience·Stéphane Potvin, Andràs Tikàsz
Dec 6, 2011·International Journal of Psychiatry in Clinical Practice·Hikaru HoriJun Nakamura
Aug 2, 2008·Clinical Neuropharmacology·Anatoly Gibel, Michael S Ritsner
Mar 6, 2009·Journal of Neurology·Roberto CavalloSimone Baldovino
Feb 14, 2016·Neuropsychological Rehabilitation·Antonio VitaEmilio Sacchetti
Jan 29, 2019·Frontiers in Pharmacology·Stefano BarlatiAntonio Vita
Nov 16, 2007·Journal of Geriatric Psychiatry and Neurology·John O Brooks, Jennifer C Hoblyn
Dec 14, 2011·European Psychiatry : the Journal of the Association of European Psychiatrists·E JohnsenE-M Løberg
Oct 16, 2007·CNS Spectrums·Timothy J OsterDavid B Arciniegas
Apr 10, 2021·L'Encéphale·O Esan, O T Ephraim-Oluwanuga
Apr 5, 2021·Neuroscience and Biobehavioral Reviews·Daniel Prates BaldezLetícia Sanguinetti Czepielewski